DSIP + Selank
The peptide sleep stack
Theoretical educational discussion
This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.
Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.
At a glance
DSIP for sleep-architecture support paired with Selank for the anxiolytic / sleep-onset arm. Both are research-grade compounds with limited human RCT evidence; the combination addresses two different sleep-disturbance patterns.
Compounds in the stack
Each compound's role in the combination, with link to its full peptide page for the underlying research.
Mechanistic rationale
The two-compound design splits sleep into two failure modes:
- Sleep-onset difficulty driven by anxiety, ruminative thinking, or cortisol dysregulation — addressed via the anxiolytic arm.
- Poor sleep architecture (light, fragmented, non-restorative sleep) — addressed via the DSIP arm.
Most pharmacologic sleep aids address one of these but not both. The peptide combination is positioned as a complementary approach without the residual sedation that benzodiazepines and z-drugs produce.
Human and emerging evidence
The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.
Reported user experiences
Potential benefits and risks
Potential benefits
- Addresses two distinct sleep failure modes (onset + architecture)
- No expected residual sedation hangover characteristic of GABAergic sleep aids
- Tolerability reports are generally favorable
- Intranasal delivery is convenient
Potential risks
- Limited human RCT evidence for either compound, let alone the combination
- DSIP's mechanism remains incompletely characterized despite five decades of research
- Long-term safety in healthy adults using these compounds chronically is unknown
- Source-quality variability in research-peptide markets
- Established sleep-hygiene and behavioral interventions have stronger evidence and should be the foundation
Open questions
- Does objective polysomnography in controlled trials confirm the subjective sleep-architecture improvements users report?
- Are there interaction risks with other sleep-aid pharmacology?
- What is the dependency / tolerance profile with chronic use?
The takeaway
The peptide sleep stack is a reasonable theoretical framing of a real two-failure-mode problem — anxiety-driven onset and poor architecture. The honest gap is that the human RCT evidence for either compound, never mind the combination, is thin. For most users with sleep concerns, the highest-evidence-supported interventions remain unglamorous — sleep hygiene, light exposure, fixed wake time, addressing caffeine and alcohol, evaluation of sleep-disordered breathing. The peptide stack lives in a more exploratory category, and is not a substitute for those foundations.
References
- Schoenenberger GA. Characterization, properties and multivariate functions of delta-sleep-inducing peptide. Eur Neurol. 1984;23(5):321-345. https://pubmed.ncbi.nlm.nih.gov/6541614/
- Kozlovskaya MM, et al. Selank and short peptides of the tuftsin family. Neurosci Behav Physiol. 2003;33(9):927-933. https://pubmed.ncbi.nlm.nih.gov/14969434/